Literature DB >> 8837317

Antiphospholipid-protein antibodies are not an uncommon feature in retinal venous occlusions.

M Coniglio1, A Platania, G D Di Nucci, P Arcieri, R Modzrewska, G Mariani.   

Abstract

The Primary Antiphospholipid Protein Syndrome (PAPS) is characterised by venous and/or arterial thromboses and recurrent foetal loss, in the presence of the Lupus Anticoagulant (LA), elevated antibodies to cardiolipin (ACA) or both. This investigation evaluates the relation between the PAPS and Retinal Vein Occlusion (RVO). Forty-eight consecutive patients with RVO were screened for ACA and LA. PAPS was present in 16 (33%) of the patients. Our results suggest that testing Antiphospholipid-Protein Antibodies (APA) may be useful in these patients, together with the assessment of other vascular risk factors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8837317     DOI: 10.1016/0049-3848(96)00119-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

1.  Ocular involvement in primary antiphospholipid syndrome. Ocular involvement in primary APS.

Authors:  F Y Demirci; R Küçükkaya; K Akarçay; N Kir; T Atamer; H Demirci; E Ongör
Journal:  Int Ophthalmol       Date:  1998       Impact factor: 2.031

2.  Hypercoagulable states in patients with retinal venous occlusion.

Authors:  A M Abu El-Asrar; A G Abdel Gader; S Al-Amro; A K Al-Momen
Journal:  Doc Ophthalmol       Date:  1998       Impact factor: 2.379

3.  Retinal vein occlusion: evaluation of "classic" and "emerging" risk factors and treatment.

Authors:  Marina Turello; Samantha Pasca; Roberto Daminato; Patrizia Dello Russo; Roberta Giacomello; Ugo Venturelli; Giovanni Barillari
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

Review 4.  [Antiphospholipid syndrome and retinal vein occlusion. Meta-analysis of Published Studies].

Authors:  M Rehak; M Müller; M Scholz; J Wiercinska; D Niederwieser; P Wiedemann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.